Medical Innovations London Ltd 09233689 false 2023-07-01 2024-06-30 2024-06-30 The principal activity of the company is the promotion of pain management and neuromodulation medical specialities by convening educational meetings in the United Kingdom and Europe Digita Accounts Production Advanced 6.30.9574.0 true true 09233689 2023-07-01 2024-06-30 09233689 2024-06-30 09233689 core:RetainedEarningsAccumulatedLosses 2024-06-30 09233689 core:ShareCapital 2024-06-30 09233689 core:CurrentFinancialInstruments 2024-06-30 09233689 core:CurrentFinancialInstruments core:WithinOneYear 2024-06-30 09233689 bus:SmallEntities 2023-07-01 2024-06-30 09233689 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-06-30 09233689 bus:FullAccounts 2023-07-01 2024-06-30 09233689 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-06-30 09233689 bus:RegisteredOffice 2023-07-01 2024-06-30 09233689 bus:Director1 2023-07-01 2024-06-30 09233689 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 09233689 bus:Agent1 2023-07-01 2024-06-30 09233689 countries:EnglandWales 2023-07-01 2024-06-30 09233689 dpl:AdministrativeExpenses 2023-07-01 2024-06-30 09233689 2023-06-30 09233689 2022-07-01 2023-06-30 09233689 2023-06-30 09233689 core:RetainedEarningsAccumulatedLosses 2023-06-30 09233689 core:ShareCapital 2023-06-30 09233689 core:CurrentFinancialInstruments 2023-06-30 09233689 core:CurrentFinancialInstruments core:WithinOneYear 2023-06-30 09233689 dpl:AdministrativeExpenses 2022-07-01 2023-06-30 09233689 2022-06-30 iso4217:GBP xbrli:pure

Registration number: 09233689

Medical Innovations London Ltd

Annual Report and Unaudited Financial Statements

for the Year Ended 30 June 2024

 

Medical Innovations London Ltd

Contents

Company Information

1

Director's Report

2

Profit and Loss Account and Statement of Retained Earnings

3

Balance Sheet

4

Notes to the Unaudited Financial Statements

5 to 7

iXBRL Detailed Profit and Loss Account

8

Accountants' Report

9

 

Medical Innovations London Ltd

Company Information

Director

Ciaran Ali Chand Wazir

Registered office

39 High Street
Battle
East Sussex
TN33 0EE

Accountants

Manningtons
39 High Street
Battle
East Sussex
TN33 0EE

 

Medical Innovations London Ltd

Director's Report for the Year Ended 30 June 2024

The director presents his report and the financial statements for the year ended 30 June 2024.

Director of the company

The director who held office during the year was as follows:

Ciaran Ali Chand Wazir

Principal activity

The principal activity of the company is the promotion of pain management and neuromodulation medical specialities by convening educational meetings in the United Kingdom and Europe

Small companies provision statement

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the director on 13 February 2025
 

.........................................
Ciaran Ali Chand Wazir
Director

 

Medical Innovations London Ltd

Profit and Loss Account and Statement of Retained Earnings for the Year Ended 30 June 2024

Note

2024
£

2023
£

Turnover

 

77,326

61,966

Administrative expenses

 

(72,659)

(56,948)

Operating profit

 

4,667

5,018

Profit before tax

4,667

5,018

Taxation

(749)

-

Profit for the financial year

 

3,918

5,018

Retained earnings brought forward

 

9,077

4,058

Retained earnings carried forward

 

12,995

9,076

The above results were derived from continuing operations.

The company has no recognised gains or losses for the year other than the results above.

 

Medical Innovations London Ltd

(Registration number: 09233689)
Balance Sheet as at 30 June 2024

Note

2024
£

2023
£

Current assets

 

Cash at bank and in hand

 

21,001

26,034

Creditors: Amounts falling due within one year

5

(8,005)

(16,957)

Net assets

 

12,996

9,077

Capital and reserves

 

Called up share capital

1

1

Retained earnings

12,995

9,076

Shareholders' funds

 

12,996

9,077

For the financial year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the director on 13 February 2025
 

.........................................
Ciaran Ali Chand Wazir
Director

 

Medical Innovations London Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
39 High Street
Battle
East Sussex
TN33 0EE
England

The principal place of business is:
Finch Hill
Langham Road
Robertsbridge
East Sussex
TN32 5DT
United Kingdom

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The presentation currency of the financial statements is the Pound Sterling (£).

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Medical Innovations London Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

4

Debtors

2024
£

2023
£

-

-

 

Medical Innovations London Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2024

5

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Taxation and social security

749

-

Accruals and deferred income

924

840

Other creditors

6,332

16,117

8,005

16,957

 

Medical Innovations London Ltd

iXBRL Detailed Profit and Loss Account for the Year Ended 30 June 2024

2024
£

2023
£

Turnover/revenue

77,326

61,966

Cost of sales

Opening stock/inventories

-

-

Closing stock/inventories

-

-

Gross profit

77,326

61,966

Distribution costs

Administrative expenses

Audit and accountancy other services

(1,008)

(960)

Subcontractor costs

(10,000)

(5,000)

Travel and subsistence

(60,239)

(48,326)

Bank charges

(45)

(44)

Printing, postage and stationery

(549)

(2,242)

Subscriptions

(40)

(231)

Other operational and administration costs

(127)

(145)

Other operating income

Other items

Operating profit

5,318

5,018

Foreign exchange loss included in non-operating income

(651)

-

Profit on ordinary activities before taxation

4,667

5,018

Tax on profit or loss on ordinary activities

(749)

-

Profit for the financial year

3,918

5,018

 

Chartered Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
Medical Innovations London Ltd
for the Year Ended 30 June 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Medical Innovations London Ltd for the year ended 30 June 2024 as set out on pages 3 to 7 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of Medical Innovations London Ltd, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Medical Innovations London Ltd and state those matters that we have agreed to state to the Board of Directors of Medical Innovations London Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Medical Innovations London Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Medical Innovations London Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Medical Innovations London Ltd. You consider that Medical Innovations London Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Medical Innovations London Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Manningtons
39 High Street
Battle
East Sussex
TN33 0EE

Date:.............................